United Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on the stock and has a $500.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein’s rating is based on the analysis of the ongoing patent litigation between United Therapeutics and Liquidia. The recent request by Judge Andrews for both companies to provide their positions on the Bayer v. Mylan decision suggests that the court is being thorough in its consideration of the case. However, a patent attorney consulted by Fein believes that the Bayer decision is unlikely to significantly impact the outcome of the UTHR v. LQDA case.
Fein’s confidence in United Therapeutics is further supported by the belief that the terms under dispute in the patent claim are not critical to the case’s outcome. The judge’s agreement with United Therapeutics on the interpretation of “maximum tolerated dose” also strengthens the company’s position. These factors contribute to Fein’s Buy rating, as they indicate a favorable legal standing for United Therapeutics in the ongoing litigation.
According to TipRanks, Fein is a 5-star analyst with an average return of 16.6% and a 51.22% success rate. Fein covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, United Therapeutics, and Savara.
In another report released today, RBC Capital also initiated coverage with a Buy rating on the stock with a $569.00 price target.